Leap Therapeutics Inc (LPTX) Opciones

touched 3 again, small prelude of things to come, imosho ANT

hearin' some good things comin' our way, hmm, u got to pay to play, ANT

Added 2,96~~ ANT

3,40~~ because they know... ANT

accumulated a nice amount around 3 bucks, longterm, ANT

3,35~~ ANT

3,33~~ ANT

Volume intact, ANT

hooverin' above 3 bucks, ceo certainly gave them somethin' to think about, to be continued.... ANT

3,33~~ ANT

3,24~~ ANT

3,19~~ ANT

mm in trouble lol, ANT

3,12~~ ANT

3,10 break is close, hmm, ANT

added some 2,80's, likin' the chart, ANT

LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

And some more 3,25's longterm, ANT

added 3,70 ANT

held first support, startin' to like this one more and more, gild support, fyi ANT

added first support, ANT

consistent buyin' often means deeper pockets like what they see or are about to find out, so they add while it's cheap, imo but we'll see soon, ANT

puppy's goin' for a new 52wk high imo ANT

because it's a double digitland stock, xcellent results will propel it imosho ANT

Any clue what's driving this major upside move the last week?

LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX under $3

LPTX under $3

LPTX under $2

LPTX under $5

LPTX...................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX 10Q due March 12

LPTX.......................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783

LPTX new 52 week low

LPTX new 52 week low

Wow..almost a year and no one posted anything!!

No one in their right mind gives 2 Sheets what some joke analyst gives for any price target

They are Shills

LPTX Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update Jan. 23
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics (LPTX) to $6 from $5 and keeps an Overweight rating on the shares. Following the ASCO GI update for DKN-01, Leap hosted a conference call on Friday to walk through the data and lay out potential next steps, the analyst notes. When considering potential treatment effect, Catanzaro thinks the signal in DKK1-high patients looks even more compelling. Leap believes it could initiate a small randomized Phase II as part of the current IND that could generate data in 2023, while simultaneously engaging regulatory agencies on registrational strategies. Most notably, BeiGene's (BGNE) opt-in decision for Asian rights will almost certainly be a 2022 event, and the analyst continues to believe the ASCO GI update should make that a straightforward choice.

yep, something big happening here.

4.08 > hod.

I think I am going to double my position on Monday

Yeah that was super strong after share offer . I think Beigene (sp?) may know this is real and we are a $10 acquisition target next year

The daily build up of short exempts on this momentum is driving the move. The cancer treatment results started the move. We shook off the share dump like it was nothing

Yes unbelievable dude . Cancer tests must be solid behind the scenes too

I got to tell you we are holding better then I thought. This may squeeze soon

yes, oddly. watch for a pull back.

Premarket looks good

yeah it's going to linger for a month now. But once Beigeine exercises their old warrants it's a good sign.